Whey predominant starter formula
OtherMilk powder product given to babies between 1 week and 4 months
NCT Number: NCT02332967
The primary objective of this trial is to demonstrate that infants receiving an infant formula in which 40 or 50% of the palmitic acid is in the sn-2 position have, during the first 4 months of life, stools that are softer than those of infants receiving a control formula.
Looking for future studies?
Notify Me1 week–4 month
All sexes
Interventional
Not applicable
Human milk is considered as the golden standard for infant formula. In human milk and infant formula lipids provide about 55% of energy for the infant and represent as such a major nutrient for the baby. The vast majority of the lipids in human milk is composed of triacylglycerols (98% of total lipids) and the remainder percent are phospholipids. Triglycerides are composed of the glycerol backbone to which three fatty acids are bound. In human milk, palmitate (16:0) is the major long chain saturated fatty acid representing 22% to 26% of total fatty acids, esterified to approximately 70% in sn-2 position on the glycerol backbone. Unsaturated fatty acids such as oleic acid (18:1) and linoleic acid (18:2n-6) are preferentially esterified at the 1 and 3 position. In infant formulas the major source of palmitic acid is palm oil or palm olein where palmitate is, however, preferentially in the external 1,3 positions, and mono- and polyunsaturated fatty acids are usually esterified at the 2-position of the triacylgycerol.
The aim of this study is to assess the safety and efficacy of infant formula containing 40% and 50%, respectively, of palmitic acid in sn-2 position.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Milk powder product given to babies between 1 week and 4 months
Milk powder product containing 40% of palmitic acid
Milk powder product containing 50% of palmitic acid
Time frame: 4 months
To demonstrate that the infants receiving an infant formula with 40% or 50% of palmitic acid during the first 4 months of life have softer stools than the ones receiving the control formula.
Time frame: 4 months
To demonstrate that the weight gain in babies receiving the experimental formula is the same as with the control formula
Time frame: 4 months
To assess whether the groups have comparable changes in length, and head circumference
Time frame: 4 months
To assess the infants' digestive tolerance of the starter formula
Time frame: 4 months
To compare gut microbiota between the groups
Time frame: 4 months
To assess fat absorption
Time frame: 4 months
To compare body composition
Time frame: 4 months
To compare volume intake between the groups
Time frame: 4 months
To compare spitting up between the groups
Time frame: 4 months
To evaluate the frequency of episodes of morbidity (adverse events)
Société des Produits Nestlé (SPN)
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06974994
Body Weight, Communicable Diseases
Turku, Valitse Maakunta., Finland
View Trial Details